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SELECTION
As discussed elsewhere in this supplement (see for
instance Fiorentino and Treasure1), the evidence base con-
cerning the practice of pulmonary metastasectomy consists
mainly of surgical follow-up studies reporting clinicopatho-
logic characteristics of patients and postmetastasectomy sur-
vival. It is in the nature of follow-up studies that the authors
retrieve data on patients who have had the operation under
review but are rarely in a position to report on the size of the
population from which they were drawn. One exception in
the case of pulmonary metastasectomy is the work of Wade et
al.2 They reported on 76 patients who had pulmonary metas-
tasectomy for colorectal cancer and, with access to registry
data, were able to report that these 76 were among 22,715
patients who had undergone surgery for primary colorectal
cancer, 2659 of whom had pulmonary metastases, with me-
tastases considered to be restricted to the lung in 514.
This high degree of selection presents a fundamental
problem when interpreting survival data (Figure 1). Cancer
patients considered for surgery have, as a group, less exten-
sive disease than those not considered surgical candidates.
For this reason, observed or perceived differences in out-
come between the two groups cannot be attributed solely to
the surgery. Gene Blackstone referred this as “the treach-
ery of work-up bias.”3
With particular reference to pulmonary metastasec-
tomy, Torkel Aberg raised the question in 1980 as to whether
the survival rates of approximately 30% at 5 years were truly
attributable to the surgery or were in reality because of the
careful selection of patients.4 The question remained unan-
swered 17 years later when he again warned caution in the
interpretation of postmetastasectomy survival.5
RESPONSES TO IMPERFECT EVIDENCE
There are three distinct responses to imperfect evidence
regarding the effectiveness of medical or surgical interventions.
One response is to rely on one’s clinical judgment to assess
whether the nature of an intervention is likely to be effective
given the accumulated knowledge and experience pertaining to
the condition in question. An extreme example of where rigor-
ous evaluation of clinical effectiveness is clearly not required is
a “mother’s kiss” to remove a bead from a child’s nostril by
blowing into its mouth.6 Cataract surgery is a more familiar
surgical example where the benefit is immediately evident. From
our own work, we would argue that a new, less burdensome way
of achieving the surgical objectives of aortic root replacement in
Marfan syndrome has self-evident benefits.7 Whether the puta-
tive mechanism whereby pulmonary metastasectomy offers sur-
vival benefit is consistent with current understanding of the
dissemination of colorectal cancer is discussed elsewhere.8
Another response is to call for better evidence. It could
be argued that, whenever faced with the possibility of selec-
tion bias, the only way to measure the benefit of surgery is to
conduct a randomized trial. However, randomized controlled
trials are expensive, demanding, can be divisive, and are
particularly challenging when the surgery in question is in
existing and widespread practice.9
Third, a complementary approach is to use modeling
to get as much information as possible from the available
data. This may involve working with survival data pertain-
ing to operated and unoperated cases to get an upper
estimate of any benefit conferred by surgery to weigh
against surgical morbidity.10 Modeling has also been used
to predict how patients undergoing a trial intervention
would have progressed had they received standard treat-
ment; the work of Jackson and Aspden11 related to acute
myeloid leukemia is a prime example.
CONSTRUCTING A COMPARATOR GROUP
Although most authors are careful to point out that
pulmonary metastasectomy patients are a carefully selected
group, implicit comparisons are made between observed
postmetastasectomy survival and survival observed among
other patients with metastatic colorectal cancer. Such com-
parison with a completely unselected group of patients,
known to have disseminated disease at diagnosis of the
primary, is not warranted.
As part of a program of research to establish whether
there is a sufficiently strong case to be made for conducting
a randomized controlled trial of pulmonary metastasectomy
in colorectal cancer, we undertook a simple modeling study,
the details of which are presented elsewhere.12 The aim of the
study was to use the extensive resource of a cancer registry to
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construct some form of comparator group against which to
assess the postmetastasectomy survival data reported in the
literature.
In doing so, we wanted to account for differences
between metastasectomy patients and the broader patient
population with colorectal cancer. We focused on two key,
linked differences between the two groups of patients. First,
although some pulmonary metastasectomy patients have dis-
seminated disease at the time that the primary colorectal
cancer is diagnosed, they predominantly have less extensive
disease13 and so, arguably, represent more indolent tumors. In
addition, there is typically an interval of 2 to 3 years between
the resection of the primary colorectal cancer and pulmonary
metastasectomy, referred to as the disease-free interval (DFI).
Again, this may be indicative of tumor indolence, and there is
the possibility that this selects those patients with a natural
course of longer survival. These two factors were chosen as
they were available in the registry and in a number of case
series reports.
We built a model to predict survival among a group of
patients matched for Dukes stage with a cohort of pulmonary
metastasectomy patients. Importantly, we predicted survival
beyond an interval following diagnosis (termed here the
“death-free interval”) with this interval analogous to and
chosen to be consistent with the “DFI” reported for the
metastasectomy patients. To populate this conditional sur-
vival model, we used raw survival data from the Thames
Cancer Registry in the UK that receives notification of cancer
diagnoses and subsequent deaths for a population of approx-
imately 12 million people. Example output of this model,
using the stage-mix and “DFI” reported by McCormack et
al.,14 can be seen in Figure 2.
SUMMARY
Considerable caution is required in interpreting the
output of the model described above. In particular, the fact
that the modeled, comparator survival curve lies within the
95% confidence interval of the observed 5-year survival
rate reported for metastasectomy should not be interpreted
as evidence that pulmonary metastasectomy is ineffective
(see Ref. 12 for a full discussion of the limitations). That
said, the findings of the simple modeling exercise under-
mine the notion that the reported 5-year survival rates of
30 to 40% after pulmonary metastasectomy in colorectal
cancer are, of themselves, sufficient proof that survival
benefit is conferred to patients by this operation. Used in
this way, as one form of evidence among many, modeling
has a useful role to play in evaluating and interpreting
non-trial data.
FIGURE 2. Comparison of output from a model con-
structed to estimate survival among a group of patients
matched for Dukes stage compared with a cohort of 144
pulmonary metastasectomy patients with colorectal cancer.
DFI refers to disease-free interval for the pulmonary metasta-
sectomy patients and to the “death-free interval” used
within the model (see text).
FIGURE 1. A pictorial representation of a selec-
tion process. Patients are ordered by two criteria
which, in addition to being criteria for selection,
are prognostic factors for survival regardless of
intervention. In this illustration, selecting on these
two criteria (dotted lines) gives a group with 40%
survival (patients depicted in smaller square in the
top right hand corner) as opposed to 5% survival
(all patients depicted).
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